Ksenia Yu. Sinichenkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ksenia Yu. Sinichenkova has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Agnesa V. Panferova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
8 shared publications - Alexander E. Druy
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
7 shared publications - Il'YA V. Sidorov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
6 shared publications - Dmitry M. Konovalov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
5 shared publications - Ruslan Kh. Abasov
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
4 shared publications - Николай Анатольевич Большаков
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
4 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 200-207
Molecular genetic landscape and current therapeutic approaches to desmoplastic small round cell tumor. Own observations and literature review
This paper presents, to our knowledge, the first reported case of desmoplastic small round cell tumor harboring a somatic missense variant in the EGFR gene in exon 21, c.2620GC (p.Gly874Arg), which did not demonstrate sensitivity to treatment with the EGFR inhibitor osimertinib. Additionally, we describe a clinical case of a patient with ovarian desmoplastic small round cell tumor carrying a pathogenic PIK3CA variant, c.263GA (p.Arg88Gln).
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 200-207
Open AccessMolecular genetic landscape and current therapeutic approaches to desmoplastic small round cell tumor. Own observations and literature review
This paper presents, to our knowledge, the first reported case of desmoplastic small round cell tumor harboring a somatic missense variant in the EGFR gene in exon 21, c.2620GC (p.Gly874Arg), which did not demonstrate sensitivity to treatment with the EGFR inhibitor osimertinib. Additionally, we describe a clinical case of a patient with ovarian desmoplastic small round cell tumor carrying a pathogenic PIK3CA variant, c.263GA (p.Arg88Gln).
- Open Access
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 34-44
Myoepithelial carcinoma of bones and soft tissues in children: a single-center experience
Introduction. Myoepithelial сarcinoma (MC) is a rare and highly malignant neoplasm. Primary soft tissue involvement predominates in pediatrics (MCST), while MC of bones has been described in isolated cases. The rarity of MC combined with its polymorphic phenotype significantly challenge diagnosis and determine the absence of standardized treatment approaches. Aim: to analyze the specifics of diagnosis and treatment of children with MC at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation. Material and methods. The study included 7 patients aged 1.3 to 14.2 years who were diagnosed with MC and registered between 2017 and 2024. Results and discussion. MC of soft tissue was diagnosed in 6/7 cases and MC of bones in 1/7. Five out of seven cases were localized, while 2/7 cases presented with distant metastases. In 3 cases a deletion of the SMARCB1 gene was identified, and in 1 case deletion of the EWSR1 gene was detected. Surgical resection proved to be the cornerstone of the treatment program for patients with MC (R0 – n = 3; R1 – n = 3; R2 – n = 1). 5 patients underwent external beam radiation therapy. In 4 cases of localized MC, courses of chemotherapy (ICpE) were administered as an adjuvant. In 1 case courses of ICpE and IVE were given perioperatively. In the first case of metastatic MCST courses of ICpE/IVE were also administered; and in the second case a combination of AP + vinorelbine was used. Follow-up outcomes: 4/7 patients are alive with 3/4 alive without events. Conclusion. The results of our study mostly align with international experience and emphasize the significance of local control, as well as the leading role of a multidisciplinary approach and multicenter data sharing in improving the diagnostic and therapeutic outcomes for patients with MC.
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 34-44
Open AccessMyoepithelial carcinoma of bones and soft tissues in children: a single-center experience
Introduction. Myoepithelial сarcinoma (MC) is a rare and highly malignant neoplasm. Primary soft tissue involvement predominates in pediatrics (MCST), while MC of bones has been described in isolated cases. The rarity of MC combined with its polymorphic phenotype significantly challenge diagnosis and determine the absence of standardized treatment approaches. Aim: to analyze the specifics of diagnosis and treatment of children with MC at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation. Material and methods. The study included 7 patients aged 1.3 to 14.2 years who were diagnosed with MC and registered between 2017 and 2024. Results and discussion. MC of soft tissue was diagnosed in 6/7 cases and MC of bones in 1/7. Five out of seven cases were localized, while 2/7 cases presented with distant metastases. In 3 cases a deletion of the SMARCB1 gene was identified, and in 1 case deletion of the EWSR1 gene was detected. Surgical resection proved to be the cornerstone of the treatment program for patients with MC (R0 – n = 3; R1 – n = 3; R2 – n = 1). 5 patients underwent external beam radiation therapy. In 4 cases of localized MC, courses of chemotherapy (ICpE) were administered as an adjuvant. In 1 case courses of ICpE and IVE were given perioperatively. In the first case of metastatic MCST courses of ICpE/IVE were also administered; and in the second case a combination of AP + vinorelbine was used. Follow-up outcomes: 4/7 patients are alive with 3/4 alive without events. Conclusion. The results of our study mostly align with international experience and emphasize the significance of local control, as well as the leading role of a multidisciplinary approach and multicenter data sharing in improving the diagnostic and therapeutic outcomes for patients with MC.
- Open Access
- 13 December 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (3) , 87-95
Aspects of molecular diagnostics and clinical characteristics of children and adolescents with CIC-rearranged sarcoma
Introduction. CIC-rearranged sarcoma is the most aggressive tumor of all undifferentiated small round cell sarcomas (USRCSs) of bone and soft tissue, characterized by a high incidence of distant metastases and disease progression during first-line treatment. In this article, we describe clinical, biological and molecular characteristics and tools for quick and precise molecular diagnosis. Aim – to evaluate the molecular features of sarcoma with CIC gene rearrangement and to investigate the clinical and prognostic characteristics in children with CIC-rearranged sarcoma. Materials and methods. We analyzed the clinical and molecular characteristics of 20 patients with the following initial morphological diagnoses: USRCS, undifferentiated spindle cell sarcoma, CIC-rearranged sarcoma. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Results. Fourteen out of 20 patients were diagnosed with CIC-rearranged sarcoma using molecular diagnostic assays. In 12 out of these 14 patients direct molecular markers were identified using RNA sequencing, in 2 patients the diagnosis was confirmed using NanoString’s molecular barcoding technology. Survival analysis was performed for 12 out of 14 patients; the 3-year overall and disease-free survival rates were 34.4 ± 16.0% and 23.8 ± 14.6%, respectively. Conclusion. Patients suspected of CIC-rearranged sarcoma always require comprehensive molecular diagnostic testing to avoid misdiagnosis. CIC-rearranged sarcoma has the most aggressive clinical course of all USRCSs, is characterized by early disease progression and requires a more intensive treatment approach.
- 13 December 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (3) , 87-95
Open AccessAspects of molecular diagnostics and clinical characteristics of children and adolescents with CIC-rearranged sarcoma
Introduction. CIC-rearranged sarcoma is the most aggressive tumor of all undifferentiated small round cell sarcomas (USRCSs) of bone and soft tissue, characterized by a high incidence of distant metastases and disease progression during first-line treatment. In this article, we describe clinical, biological and molecular characteristics and tools for quick and precise molecular diagnosis. Aim – to evaluate the molecular features of sarcoma with CIC gene rearrangement and to investigate the clinical and prognostic characteristics in children with CIC-rearranged sarcoma. Materials and methods. We analyzed the clinical and molecular characteristics of 20 patients with the following initial morphological diagnoses: USRCS, undifferentiated spindle cell sarcoma, CIC-rearranged sarcoma. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Results. Fourteen out of 20 patients were diagnosed with CIC-rearranged sarcoma using molecular diagnostic assays. In 12 out of these 14 patients direct molecular markers were identified using RNA sequencing, in 2 patients the diagnosis was confirmed using NanoString’s molecular barcoding technology. Survival analysis was performed for 12 out of 14 patients; the 3-year overall and disease-free survival rates were 34.4 ± 16.0% and 23.8 ± 14.6%, respectively. Conclusion. Patients suspected of CIC-rearranged sarcoma always require comprehensive molecular diagnostic testing to avoid misdiagnosis. CIC-rearranged sarcoma has the most aggressive clinical course of all USRCSs, is characterized by early disease progression and requires a more intensive treatment approach.
- Open Access
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 103-112
RET-rearranged spindle cell soft tissue sarcoma in children: description of a clinical case and literature review
Soft tissue sarcomas (SMTs) represent a heterogeneous group of malignant tumors of mesenchymal origin. The widespread introduction of next-generation sequencing techniques, including RNA sequencing, into clinical practice has led to the description of a variety of SMTs with rearrangements of genes encoding various kinases. The present article describes the clinical case of a 3-year-old patient with a low-grade spindle cell sarcoma with a detectable MYH10::RET RNA transcript. The literature review describes the role of the RET gene in the pathogenesis of malignant neoplasms, with emphasis on soft tissue tumors, and presents the clinical, molecular and genetic characteristics of pediatric cases of SMT with RET gene rearrangements and the results of their therapy. The role of various molecular oncology techniques in the identification of kinase gene rearrangements, including RET, is discussed.
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 103-112
Open AccessRET-rearranged spindle cell soft tissue sarcoma in children: description of a clinical case and literature review
Soft tissue sarcomas (SMTs) represent a heterogeneous group of malignant tumors of mesenchymal origin. The widespread introduction of next-generation sequencing techniques, including RNA sequencing, into clinical practice has led to the description of a variety of SMTs with rearrangements of genes encoding various kinases. The present article describes the clinical case of a 3-year-old patient with a low-grade spindle cell sarcoma with a detectable MYH10::RET RNA transcript. The literature review describes the role of the RET gene in the pathogenesis of malignant neoplasms, with emphasis on soft tissue tumors, and presents the clinical, molecular and genetic characteristics of pediatric cases of SMT with RET gene rearrangements and the results of their therapy. The role of various molecular oncology techniques in the identification of kinase gene rearrangements, including RET, is discussed.
- Open Access
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Molecular and Clinical Characteristics of Sarcomas with BCOR Genetic Alteration in Children and Adolescents
Введение. Саркома с аберрацией гена BCOR представляет собой относительно недавно охарактеризованную группу опухолей, характеризующуюся аберрациями гена BCOR, приводящих к его онкогенной активации, в результате чего они имеют разнообразное клиническое поведение, отличное от саркомы Юинга (СЮ), с которой данные опухоли имеют определенное морфологическое сходство. Морфологический диагноз в подавляющем большинстве случаев оказывается верен, однако для его подтверждения порой приходится прибегать к многообразию методик молекулярной диагностики для определения прямых или суррогатных диагностических маркеров. Материалы и методы. В исследование вошло 23 пациента с молекулярно-подтвержденным диагнозом саркомы с аберрацией гена BCOR при помощи ОТ-ПЦР, секвенирования РНК или метода цифрового баркодирования РНК Nanostring. Всем пациентам проведена оценка клинических данных и показателей общей и бессобытийной выживаемости в зависимости от проведенного лечения методом Каплана — Майера. Результаты. У 22 (96 %) пациентов из 23 входящим морфологическим диагнозом являлась саркома с аберрацией гена BCOR, у одного (4 %) пациента — недифференцированная мелкокруглоклеточная саркома (НМКкС). Морфологический диагноз был подтвержден в 17 из 23 случаев методом ОТ-ПЦР, в двух случаях — с пограничным качеством выделенной РНК методом цифрового баркодирования РНК Nanostring, у четверых — методом высокопроизводительного секвенирования с обнаружением более редких аберраций — BCOR ITD (ex15), BCOR::MAML3 (ex15::ex2) и YWHAE::NUTM2B (ex5::ex2). Медиана возраста на момент заболевания составила 10,5 (0,25–16,4) года. Локализованная форма была диагностирована в 17 (74 %) случаях, в 6 (26 %) определялись отдаленные метастазы. 13 (57 %) пациентов получали лечение в соответствии с протоколами Euro Ewing-2008 и 2012, 10 (43 %) — CWS-2009. Рецидив развился у восьми человек (35 %), у шести из восьми — локальный, у двух — системный. Общая трехлетняя выживаемость среди 23 пациентов составила 96,0 ± 0,04 %, бессобытийная выживаемость — 66,8 ± 0,12 %. Выводы. Для пациентов с наиболее часто встречаемой перестройкой BCOR::CCNB3 характерны индолентное течение, тропность к костям осевого скелета и преобладание у лиц мужского пола. При сравнении бессобытийной выживаемости в зависимости от использования юинг-ориентированного протокола лечения или протокола лечения для мягкотканых сарком достоверной разницы не получено.
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Open AccessMolecular and Clinical Characteristics of Sarcomas with BCOR Genetic Alteration in Children and Adolescents
Введение. Саркома с аберрацией гена BCOR представляет собой относительно недавно охарактеризованную группу опухолей, характеризующуюся аберрациями гена BCOR, приводящих к его онкогенной активации, в результате чего они имеют разнообразное клиническое поведение, отличное от саркомы Юинга (СЮ), с которой данные опухоли имеют определенное морфологическое сходство. Морфологический диагноз в подавляющем большинстве случаев оказывается верен, однако для его подтверждения порой приходится прибегать к многообразию методик молекулярной диагностики для определения прямых или суррогатных диагностических маркеров. Материалы и методы. В исследование вошло 23 пациента с молекулярно-подтвержденным диагнозом саркомы с аберрацией гена BCOR при помощи ОТ-ПЦР, секвенирования РНК или метода цифрового баркодирования РНК Nanostring. Всем пациентам проведена оценка клинических данных и показателей общей и бессобытийной выживаемости в зависимости от проведенного лечения методом Каплана — Майера. Результаты. У 22 (96 %) пациентов из 23 входящим морфологическим диагнозом являлась саркома с аберрацией гена BCOR, у одного (4 %) пациента — недифференцированная мелкокруглоклеточная саркома (НМКкС). Морфологический диагноз был подтвержден в 17 из 23 случаев методом ОТ-ПЦР, в двух случаях — с пограничным качеством выделенной РНК методом цифрового баркодирования РНК Nanostring, у четверых — методом высокопроизводительного секвенирования с обнаружением более редких аберраций — BCOR ITD (ex15), BCOR::MAML3 (ex15::ex2) и YWHAE::NUTM2B (ex5::ex2). Медиана возраста на момент заболевания составила 10,5 (0,25–16,4) года. Локализованная форма была диагностирована в 17 (74 %) случаях, в 6 (26 %) определялись отдаленные метастазы. 13 (57 %) пациентов получали лечение в соответствии с протоколами Euro Ewing-2008 и 2012, 10 (43 %) — CWS-2009. Рецидив развился у восьми человек (35 %), у шести из восьми — локальный, у двух — системный. Общая трехлетняя выживаемость среди 23 пациентов составила 96,0 ± 0,04 %, бессобытийная выживаемость — 66,8 ± 0,12 %. Выводы. Для пациентов с наиболее часто встречаемой перестройкой BCOR::CCNB3 характерны индолентное течение, тропность к костям осевого скелета и преобладание у лиц мужского пола. При сравнении бессобытийной выживаемости в зависимости от использования юинг-ориентированного протокола лечения или протокола лечения для мягкотканых сарком достоверной разницы не получено.
- Open Access
- 28 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1) , 175-180
CIC-rearranged sarcoma mimicking pseudotumor in a patient with hemophilia A
Hemophilic pseudotumor is a rare complication occurring in 1–2% of cases and resulting from a recurrent chronic muscle hematoma. We describe a clinical case of a child suffering from hemophilia type A who was admitted with a forearm mass, interpreted as a pseudotumor. However, histological examination of the mass revealed a rare aggressive CIC-rearranged sarcoma. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
- 28 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1) , 175-180
Open AccessCIC-rearranged sarcoma mimicking pseudotumor in a patient with hemophilia A
Hemophilic pseudotumor is a rare complication occurring in 1–2% of cases and resulting from a recurrent chronic muscle hematoma. We describe a clinical case of a child suffering from hemophilia type A who was admitted with a forearm mass, interpreted as a pseudotumor. However, histological examination of the mass revealed a rare aggressive CIC-rearranged sarcoma. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
- Open Access
- 28 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1)
CIC-перестроенная саркома мимикрирующая псевдоопухоль у пациента с гемофилией.
Pediatric Hematology/Oncology and Immunopathology | Peer-rewiev medical journal Вопросы гематологии/онкологии и иммунопатологии в педиатрии | Научный рецензируемый журнал
- 28 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1)
Open AccessCIC-перестроенная саркома мимикрирующая псевдоопухоль у пациента с гемофилией.
Pediatric Hematology/Oncology and Immunopathology | Peer-rewiev medical journal Вопросы гематологии/онкологии и иммунопатологии в педиатрии | Научный рецензируемый журнал
- Open Access
- 17 July 2024
- Published by Impact Journals, LLC in Oncotarget
- Vol. 15 (1) , 493-500
Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors
Https://doi.org/10.18632/oncotarget.28606 Kseniya Sinichenkova, Iliya Sidorov, Nataliya Kriventsova, Dmitriy Konovalov, Ruslan Abasov, Nataliya Usman, Alexander Karachunskiy, Galina Novichkova,...
- 17 July 2024
- Published by Impact Journals, LLC in Oncotarget
- Vol. 15 (1) , 493-500
Open AccessRapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors
Https://doi.org/10.18632/oncotarget.28606 Kseniya Sinichenkova, Iliya Sidorov, Nataliya Kriventsova, Dmitriy Konovalov, Ruslan Abasov, Nataliya Usman, Alexander Karachunskiy, Galina Novichkova,...
- Open Access
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 127-133
Intracranial mesenchymal tumors with FET–CREB fusion
Intracranial mesenchymal tumors with rearrangements of the genes of the FET and CREB families were first described in the 2021 World Health Organization classification of tumors of the central nervous system. At the moment, the criteria for the diagnosis and treatment of these tumors have not been unambiguously defined. This article presents two exceptionally rare clinical cases of adolescent patients with IMT with the presence of gene rearrangement of the FET and CREB gene families, who were treated and examined at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The patients’ parents gave consent to the use of their children's data, including photographs, for research purposes and in publications.
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 127-133
Open AccessIntracranial mesenchymal tumors with FET–CREB fusion
Intracranial mesenchymal tumors with rearrangements of the genes of the FET and CREB families were first described in the 2021 World Health Organization classification of tumors of the central nervous system. At the moment, the criteria for the diagnosis and treatment of these tumors have not been unambiguously defined. This article presents two exceptionally rare clinical cases of adolescent patients with IMT with the presence of gene rearrangement of the FET and CREB gene families, who were treated and examined at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The patients’ parents gave consent to the use of their children's data, including photographs, for research purposes and in publications.
- Open Access
- 24 October 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 981230
Case report: First case of undifferentiated embryonal sarcoma of the liver in a child with neurofibromatosis type 1, treated by hepatic chemoperfusion with transcatheter arterial chemoembolization
Introduction: In this report we firstly describe undifferentiated embryonal sarcoma of the liver (UESL) in a patient with neurofibromatosis type 1 (NF1), fatally complicated by synchronous malignant peripheral nerve sheath tumor (MPNST) with a highly aggressive metastatic course. The case also represents our first experience of chemoperfusion involving the transcatheter arterial chemoembolization (TACE) in a pediatric patient, applied as a treatment for UESL.Case presentation: A 13-year-old girl was diagnosed with NF1 and presented with a liver tumor identified as UESL by histological assessment. The tumor was refractive to the conventional first-line chemotherapy. The patient received hepatic chemoperfusion with TACE, which was efficacious; however, the overall curative outcome was unsatisfactory due to synchronous unresectable retroperitoneal MPNST with mesenteric metastases and ultimate progression of the UESL.Conclusion: This is the first reported case of UESL in a patient with NF1. The results demonstrate the efficacy of hepatic chemoperfusion with TACE in pediatric UESL.
- 24 October 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 981230
Open AccessCase report: First case of undifferentiated embryonal sarcoma of the liver in a child with neurofibromatosis type 1, treated by hepatic chemoperfusion with transcatheter arterial chemoembolization
Introduction: In this report we firstly describe undifferentiated embryonal sarcoma of the liver (UESL) in a patient with neurofibromatosis type 1 (NF1), fatally complicated by synchronous malignant peripheral nerve sheath tumor (MPNST) with a highly aggressive metastatic course. The case also represents our first experience of chemoperfusion involving the transcatheter arterial chemoembolization (TACE) in a pediatric patient, applied as a treatment for UESL.Case presentation: A 13-year-old girl was diagnosed with NF1 and presented with a liver tumor identified as UESL by histological assessment. The tumor was refractive to the conventional first-line chemotherapy. The patient received hepatic chemoperfusion with TACE, which was efficacious; however, the overall curative outcome was unsatisfactory due to synchronous unresectable retroperitoneal MPNST with mesenteric metastases and ultimate progression of the UESL.Conclusion: This is the first reported case of UESL in a patient with NF1. The results demonstrate the efficacy of hepatic chemoperfusion with TACE in pediatric UESL.